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Editorial
Prophylactic vaccines for patients with human 
papillomavirus diseases (HPV)☆
Vacinação profi lática para pacientes com doenças causadas 
pelo papilomavírus humano (HPV)
The presence of types 16 and 18 in 70-76% of carcinomas of 
the uterine cervix, and in 63-95% of anogenital tumours, un-
derscores the need for prevention for this disease.1 Among the 
tools available for this task, prophylactic HPV vaccines appear 
to be the most promising. Added to this, a meta-analysis su-
ggested that 80% of anal carcinomas could be prevented by 
vaccination against these serotypes.2
Currently, two vaccines are available: bivalent (bHPV) and 
quadrivalent (qHPV), whose prospective studies showed effi -
cacy against specifi c types of HPV and suffi cient evidence for 
their use.3,4 bHPV immunizes against HPV types 16 and 18, 
and qHPV, besides these, immunizes against HPV types 6 and 
11, that are responsible for 90% of warty lesions in this area.3 
Both vaccines use virus-like particles (VLP) to generate neu-
tralizing antibodies against L1, the major protein of the viral 
capsid.5
The primary goal of these vaccines is to prevent anoge-
nital carcinoma. The assessment of their effectiveness is ba-
sed on the possibility of preventing persistent infection and 
intraepithelial neoplasia, the precursor lesion of carcinoma. 
Phase I and II clinical trials have shown the safety of these 
vaccines and their ability to produce very high levels of anti-
bodies, which are low or nonexistent after natural infection. 
Phase II and III trials confi rm these features, showing almost 
100% effi cacy to prevent infection and intraepithelial neopla-
sia associated with oncogenic types immunized by the vac-
cines. Other studies have observed cross-protection against 
infection by other oncogenic HPV types, such as 31 and 45.6 
Regarding the time of immunization conferred by these types, 
it is possible to state that the clinical trial with longer follow-
-up of qHPV amounts currently to 10 years, and serologic tests 
demonstrate that the antibody level remains high.7
The Agência Nacional de Vigilância Sanitária (ANVISA) (Na-
tional Health Surveillance Agency) has released vaccine appli-
cation both for women and men aged 9 to 26 years old, provi-
ded they have not yet started their sexual life or had contact 
with the HPV types involved in immunization.8 qHPV vaccine 
is given intramuscularly in three doses, with the second and 
third doses applied two and six months after the fi rst. In the 
case of bHPV the scheme is the same, but with the second and 
third doses applied one and six months after the initial dose.
At moment, we still do not know if there will be a need 
for a booster or a new vaccination.7 It is important to note 
that HPV vaccination is no substitute for routine screening 
for cervical cancer, as is currently recommended. Although 
condoms prevent contamination in the vast majority of cases, 
there is no effective way to prevention, except by complete 
sexual abstinence.9 The treatment of warts and cytological 
abnormalities consists of the removal of affected cells and in 
a follow-up for detection of recurrences.
Although the government agencies indicate that the vacci-
nation should be applied between the ages of 9 and 26, qHPV 
was effective in women between 24 and 45 years who were 
not already infected with HPV types.10 Other clinical trials 
have shown qHPV usefulness in women under 55 years old.11 
The rate of new infections declines with age and typically 
does not progress to high-grade cervical intraepithelial ne-
oplasia (CIN) in older women. Because of this, the potential 
benefi t of prophylactic vaccination at older ages is low.12 
Defi nitely, the vaccines do not treat pre-existing infections 
or HPV-induced lesions.5,13 Aiming that, therapeutic vaccines 
are being developed, in order to stimulate cellular immunity 
against infected cells.13 Prophylactic vaccines can only pre-
vent infections by HPV types against which immunized pe-
ople were not contaminated,14 even if they have previous or 
current history of HPV-induced lesion.
However, it was observed among those who participated in 
clinical trials for qHPV and who progressed with anogenital 
HPV infection that the best results in the follow-up were no-
ted among those who received all three doses of the vaccine, 
compared with those in placebo group. In a group of 17,622 
women aged 15 to 26 years, 587 of the vaccinated group and 
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763 who had received placebo had their clinical and subcli-
nical HPV cervical lesions resected. Recurrences occurred in 
6.6% and 12.2%, respectively.
These data have statistical difference, and the authors 
concluded that the vaccine caused a reduction of relapses 
and of high-grade CIN.15
In another study of 18,174 women, of whom 15% had evi-
dence of infection by immunized types, it was found that 
the vaccine appeared to prevent reinfection and reactiva-
tion of the disease for these viral types.16 A report involving 
602 men aged 16 to 26 who received qHPV revealed that the 
rates of appearance of infection by HPV types were 17.5% 
and 13%, whereas the reduction of high-grade intraepithe-
lial anal neoplasia (IAN) occurred in 54.2% and 74.9%, and 
the reduction of relapses was 59.4% and 94.9%, respective-
ly, among those who received placebo and those who were 
vaccinated.17
Yet in another study, 36 men aged 16 to 26 who received 
qHPV and 89 in the placebo group developed genital warts. 
After treatment, persistent infection was better controlled in 
those of the vaccinated group, 47.8% and 27.1%, respectively.18 
However, in a study of bHPV that included 419 women in the 
vaccine group and 440 in the placebo group and who had evi-
dence of prior infection with types 16 and 18, the evaluation 
of the results of this subgroup suggested that bHPV neither 
improved nor reduced the progression of high-grade CINs, 
and that the cytological screening should be recommended.19
These data suggest that qHPV may have influenced the 
best evolution of carriers of HPV types. And some researchers 
suggest the use of qHPV as adjunctive therapy in patients with 
recurring lesions20 and high-grade CIN.21 It is known that the 
HPV present in warts and in subclinical lesions continuously 
reinfects those with this infection. When penetrating the epi-
thelium, the viral particles reach and invade the basal layer 
cells of the host, which may perpetuate the infection. Among 
those vaccinated, the presence of viral antibodies would pre-
vent this action, interrupting self-contamination.
However, the established disease should be treated, be-
cause as long as there is cell contamination the infection will 
persist and new lesions may appear.
These results bring great encouragement to people with 
diseases caused by HPV and to those responsible for their 
treatment. However, further studies with larger numbers of 
cases and longer evolution times are needed to confirm this 
observation, before the vaccination against this virus can be 
definitely authorized by the competent agencies.
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